drugset / Trial / NCT05464953

Suprachoroidal Triamcinolone Versus Posterior Subtenon Triamcinolone Alone or Formulated in the Management of Diabetic Macular Edema.

NCT05464953

Completed 75 enrolled Al-Azhar University
RandomizedParallel-groupOpen-labelTreatment

Summary

Background Retinal vascular disorders, such as diabetic retinopathy, hypertensive retinopathy, retinal hemorrhage, and retinal vein occlusion are significant causes of vision impairment and blindness worldwide. Diabetic retinopathy (DR) is the most common retinal vascular disorder and is the leading cause of vision loss among patients aged 25 to 74 years. Aim to compare formulated Posterior Subtenon Triamcinolone acetonide (PSTA) injection versus Posterior Subtenon Triamcinolone acetonide alone versus suprachoroidal triamcinolone in the management of diabetic macular edema.

Timeline

Start
2020-01-20
Primary completion
2022-04-20
Completion
2022-04-30

Drugs

EvaluationDrugModalityDoseRoute
Comparator Triamcinolone Other / unclassified Other
Comparator Triamcinolone Acetonide Other / unclassified Other